ATE135235T1 - Heilungsverfahren unter verwendung katalytischer antikörper - Google Patents

Heilungsverfahren unter verwendung katalytischer antikörper

Info

Publication number
ATE135235T1
ATE135235T1 AT89906520T AT89906520T ATE135235T1 AT E135235 T1 ATE135235 T1 AT E135235T1 AT 89906520 T AT89906520 T AT 89906520T AT 89906520 T AT89906520 T AT 89906520T AT E135235 T1 ATE135235 T1 AT E135235T1
Authority
AT
Austria
Prior art keywords
antibodies
disclosed
hapten
catalytic antibodies
antigens
Prior art date
Application number
AT89906520T
Other languages
English (en)
Inventor
Michael J Powell
Anthony R Rees
Richard J Massey
Original Assignee
Igen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igen Inc filed Critical Igen Inc
Application granted granted Critical
Publication of ATE135235T1 publication Critical patent/ATE135235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT89906520T 1988-05-04 1989-05-04 Heilungsverfahren unter verwendung katalytischer antikörper ATE135235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19027188A 1988-05-04 1988-05-04

Publications (1)

Publication Number Publication Date
ATE135235T1 true ATE135235T1 (de) 1996-03-15

Family

ID=22700646

Family Applications (3)

Application Number Title Priority Date Filing Date
AT89906520T ATE135235T1 (de) 1988-05-04 1989-05-04 Heilungsverfahren unter verwendung katalytischer antikörper
AT95111577T ATE246004T1 (de) 1988-05-04 1989-05-04 Heilungsverfahren unter verwendung katalytischer antikörper
AT89906570T ATE194649T1 (de) 1988-05-04 1989-05-04 Peptidanaloge und deren verwendung als haptene zum auslösen katalytischer antikörper

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT95111577T ATE246004T1 (de) 1988-05-04 1989-05-04 Heilungsverfahren unter verwendung katalytischer antikörper
AT89906570T ATE194649T1 (de) 1988-05-04 1989-05-04 Peptidanaloge und deren verwendung als haptene zum auslösen katalytischer antikörper

Country Status (9)

Country Link
EP (3) EP0701818B1 (de)
JP (3) JP2931609B2 (de)
AT (3) ATE135235T1 (de)
AU (2) AU638405B2 (de)
CA (2) CA1341478C (de)
DE (3) DE68925972T2 (de)
IL (1) IL90200A (de)
WO (2) WO1989010754A1 (de)
ZA (1) ZA893284B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025573A1 (en) * 1993-04-23 1994-11-10 Igen, Inc. Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US6521432B1 (en) 1988-05-04 2003-02-18 Igen International, Inc. Methods for enhancing the rate of modification of metastable bonds
US6702705B1 (en) 1988-05-04 2004-03-09 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
DK0454783T3 (da) * 1989-01-23 1995-10-16 Akzo Nobel Nv Sted-specifik in vivo aktivering af terapeutiske lægemidler
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
WO1990015074A1 (en) * 1989-06-08 1990-12-13 Igen, Inc. Methods for enhancing the rate of modification of metastable bonds
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
ES2078518T3 (es) * 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
WO1993006838A1 (en) * 1991-10-02 1993-04-15 The Scripps Research Institute Molecules with antibody combining sites that catalyze glycosidic reactions
US5302707A (en) * 1992-03-26 1994-04-12 Affymax Technologies N.V. 5-fluorouridine nucleoside phosphate compounds
IL105131A (en) * 1992-03-27 2000-06-01 Igen Inc Compounds and compositions containing such compounds comprising lipid-A analogs for eliciting therapeutic antibodies
US6156541A (en) * 1995-07-21 2000-12-05 The Board Of Regents Of The University Of Nebraska Compositions and methods for catalyzing hydrolysis of HIV gp120
EP1001805A1 (de) * 1997-06-18 2000-05-24 The Rockefeller University Verfahren zur identifizierung von antikörpern und peptiden für die behandlung von septischen schock und experimenteller arthritis und verwendungen
IT1293511B1 (it) * 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
EP1358178A2 (de) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamidlactam-inhibitoren von faktor xa
WO2005077984A1 (ja) * 2004-02-13 2005-08-25 Osaka Industrial Promotion Organization 有機化合物の製造方法およびそれに用いる抗体
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
JP4861019B2 (ja) * 2006-01-31 2012-01-25 独立行政法人科学技術振興機構 ヒトＴＮＦ−αに対する抗体酵素およびその利用
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
JP2010540527A (ja) 2007-09-25 2010-12-24 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物
PT3412676T (pt) 2010-08-10 2020-05-19 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico, método para a sua preparação e suas utilizações terapêuticas
MX350974B (es) 2010-11-18 2017-09-27 Univ Yale Moleculas bifuncionales con actividad reclutadora de anticuerpos e inhibidora de la entrada frente al virus de inmunodeficiencia humana.
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014160305A1 (en) * 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
SMT201900611T1 (it) 2014-05-05 2020-01-14 Rempex Pharmaceuticals Inc Sintesi di sali boronati e usi degli stessi
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2761778T3 (es) 2014-12-19 2020-05-21 Rempex Pharmaceuticals Inc Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
JP2023524525A (ja) 2020-05-05 2023-06-12 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体、ならびにその合成、多形体、および治療的使用
CN113307863B (zh) * 2021-05-25 2022-12-16 华南农业大学 一种聚天冬氨酸及其盐类抗体的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
JP2540508B2 (ja) * 1983-11-29 1996-10-02 イージエン・インコーポレイテッド 化学反応を触媒する方法
US5030717A (en) * 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US4659567A (en) 1984-09-07 1987-04-21 Scripps Clinic & Research Foundation Molecules with antibody combining sites that bind to hydrolytic transition states
US4792446A (en) * 1986-06-23 1988-12-20 Igen, Inc. Production of antibody catalysts
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US5079152A (en) * 1987-05-28 1992-01-07 Scripps Clinic And Research Foundation Antibody combining sites that exhibit stereoselective synthase activity, and methods using the same
ES2051804T3 (es) * 1987-09-02 1994-07-01 Igen Inc Produccion de catalizadores de inmunoproximidad.
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction

Also Published As

Publication number Publication date
DE68929479T2 (de) 2004-04-15
JP2931609B2 (ja) 1999-08-09
ATE246004T1 (de) 2003-08-15
CA1341478C (en) 2005-04-05
EP0436545B1 (de) 1996-03-13
EP0413762A4 (en) 1992-01-15
AU643186B2 (en) 1993-11-11
DE68929230D1 (de) 2000-08-17
EP0436545A1 (de) 1991-07-17
DE68929230T2 (de) 2001-02-22
AU3730489A (en) 1989-11-29
JPH05501948A (ja) 1993-04-15
JP2772088B2 (ja) 1998-07-02
EP0701818A2 (de) 1996-03-20
AU3739389A (en) 1989-11-29
JPH11152232A (ja) 1999-06-08
EP0436545A4 (de) 1991-05-30
CA1340485C (en) 1999-04-06
AU638405B2 (en) 1993-07-01
JPH03504130A (ja) 1991-09-12
DE68925972D1 (de) 1996-04-18
EP0701818B1 (de) 2003-07-30
ATE194649T1 (de) 2000-07-15
IL90200A (en) 1997-04-15
DE68925972T2 (de) 1996-07-25
EP0701818A3 (de) 1997-06-04
ZA893284B (en) 1990-03-28
EP0413762A1 (de) 1991-02-27
WO1989010754A1 (en) 1989-11-16
DE68929479D1 (de) 2003-09-04
WO1989010961A1 (en) 1989-11-16
EP0413762B1 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
DE68925972D1 (de) Heilungsverfahren unter verwendung katalytischer antikörper
PT91381A (pt) Processo para a preparacao microbiologica de albumina de soro humano e de outras proteinas heterologas a partir de levedura
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
EP1293565A3 (de) RNA-Komponente der Telomerase von Säugetieren
AU1520895A (en) Purified primate ctla-8 antigens and related reagents
EP1477561A3 (de) Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen
CA2263129A1 (en) Mammalian cell surface antigens; related reagents
NO970740L (no) Glutamat reseptor
WO1997021812A3 (en) Mammalian chemokine ccf8 and chemokine receptor cckr3
EP1803816A3 (de) Zelloberflächen-Antigene aus Säugetieren und verwandte Reagenzien
RU93005166A (ru) Структурированные кристаллы в качестве нового вида ферментной иммобилизации
WO2003045975A3 (en) Solid-phase immobilization of proteins and peptides
AU2002254892A1 (en) Sorting and immobilization system for nucleic acids using synthetic bidning systems
WO2000042188A3 (en) Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
NO975714D0 (no) Fremgangsmåte for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmasöytisk blanding og diagnostisk reagens inneholdende samme
WO1998011226A3 (en) Mammalian chemokines, related reagents
WO1998032858A3 (en) Mammalian chemokines; receptors; reagents; uses
CA2066263A1 (en) Tsh receptor
WO1999004266A3 (en) Interactions of atm, atr or dna-pk with p53
JPS6488367A (en) Immobilized antibody
EP0324603A3 (de) Festphasen-Enzymimmuntest-Vorrichtung und Verfahren zum Nachweis von Antikörpern
WO1998031810A3 (en) Mammalian chemokines; receptors; reagents; uses
WO2000023182A3 (en) Method of bonding bio-molecules to a test site
AU7903594A (en) Antigens containing metastable bonds
WO2000034335A3 (en) 'death domain' containing receptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee